ResearcherAffiliated Hangzhou First People's Hospital, Westlake University, School of MedicineActive in the last 2 years

Hangbin Jin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5746-1612; OpenAlex author ID A5101707844. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 2

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xiaofeng Zhang · 1 shared paper, 2025 · strength 0.33
- Paper Efficacy and safety of early pancreatic duct stenting for unresectable pancreatic cancer: A randomized controlled trial. DOI 10.4251/wjgo.v17.i4.103311 ↗
Min-Hui Sun · 1 shared paper, 2025 · strength 0.33
- Paper Efficacy and safety of early pancreatic duct stenting for unresectable pancreatic cancer: A randomized controlled trial. DOI 10.4251/wjgo.v17.i4.103311 ↗
Hongzhang Shen · 1 shared paper, 2025 · strength 0.33
- Paper Efficacy and safety of early pancreatic duct stenting for unresectable pancreatic cancer: A randomized controlled trial. DOI 10.4251/wjgo.v17.i4.103311 ↗
Jianfeng Yang · 1 shared paper, 2018 · strength 0.11
- Paper Hyperthermia enhances the sensitivity of pancreatic cancer SW1990 cells to gemcitabine through ROS/JNK signaling. DOI 10.3892/ol.2018.9455 ↗
Shenglin Ma · 1 shared paper, 2018 · strength 0.11
- Paper Hyperthermia enhances the sensitivity of pancreatic cancer SW1990 cells to gemcitabine through ROS/JNK signaling. DOI 10.3892/ol.2018.9455 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.